AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle.
"We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie.
"Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes.
This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies.
About AtomVie Global Radiopharma (AtomVie)
AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit https://www.atomvie.com/
About TerraPower Isotopes (TPI)
TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at https://www.terrapower.com/isotopes/
About TerraPower
TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs.
SOURCE AtomVie Global Radiopharma Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
4 hours ago
- Toronto Star
Melcor Developments announces second quarter results, declares quarterly dividend of $0.13 per share
EDMONTON, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) — Melcor Developments Ltd. ('Melcor') (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the second quarter ended June 30, 2025. The second quarter Management Discussion & Analysis (MD&A) and Condensed Interim Financial Statements are available on our website ( under Investors, or on SEDAR+ ( Timothy Melton, Melcor's Executive Chair and Chief Executive Officer, commented: 'Melcor is pleased to report results for the second quarter of 2025. Consolidated revenues year-to-date reached $150.88 million, a 26.3% increase over 2024 . Gross margin also saw an improvement, which was up to 54.6%, from a gross margin of 49.1% to date last year. Funds from operations increased 36.7% to $85.96 million year-to-date (2024: $62.88 million) the result of strong performance across our operating divisions.
Calgary Herald
5 hours ago
- Calgary Herald
Cohere hits US$6.8-billion valuation and snags Meta's former AI head
Canada's top-funded artificial intelligence startup has secured a US$500 million fundraise that boosts Cohere Inc. 's valuation to US$6.8 billion as it tries to become a mainstay in a heavily funded and increasingly competitive race to supply businesses and governments with AI services. Article content The Toronto-headquartered company has also added a key figure to its AI personnel by hiring Meta Platforms Inc. 's former AI head Joelle Pineau as its chief AI officer. Pineau will lead the company's research and product development efforts from Montreal, where Cohere opened a new office last month – its second in Canada. Article content Article content Its latest funding round was led by Toronto-based Radical Ventures Investments Inc. and Montreal-based Inovia Capital Inc., and included participation from existing investors such as chip behemoth Nvidia Corp., AMD Ventures, the venture capital arm of Advanced Micro Devices Inc., and the Healthcare of Ontario Pension Plan. Article content Its valuation has shot up from US$5.5 billion since its last funding round in June 2024 and has soared 200 per cent since its June 2023 fundraising round. Article content Article content Though Cohere's size and business remain small compared to its Silicon Valley peers — the likes of OpenAI Inc. and Anthropic PBC, which are targeting valuations of US$300 billion and US$170 billion, respectively — it is hedging its bets on helping businesses and governments worldwide integrate its AI models and systems. Article content Article content For example, it teamed up in January with the Royal Bank of Canada, the country's biggest bank and most valuable company, to develop North for Banking, an AI platform for financial services. Article content More recently, Cohere has announced a slew of private- and public-sector deals, in addition to new offices in Montreal and Seoul, South Korea. Article content In early August, Cohere launched its AI agent service and is working with 'large enterprises across key markets in North America, APAC, and EMEA' to integrate the platform. Last month, the company struck an alliance with BCE Inc. to sell AI tools to Canadian organizations.
Toronto Star
5 hours ago
- Toronto Star
Kellogg says it will remove artificial dyes from cereals by the end of 2027
NEW YORK (AP) — WK Kellogg Co. plans to remove artificial dyes from its breakfast cereals in the next two and a half years, according to the company and the attorney general of Texas. The maker of Froot Loops and Apple Jacks gave the timeline as U.S. food producers face increasing pressure from the U.S. government and consumers to phase out synthetic colorings from their products. Texas Attorney General Ken Paxton said Wednesday that Kellogg had signed an agreement assuring his office that the Michigan-based company would 'permanently remove toxic dyes' from its cereals by the end of 2027.
